Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.provenance | CONICET | - |
dc.creator | Austin, Matthew | - |
dc.creator | Yang, Yu Ching | - |
dc.creator | Vittinghoff, Eric | - |
dc.creator | Adami, Silvano | - |
dc.creator | Boonen, Steven | - |
dc.creator | Bauer, Douglas C | - |
dc.creator | Bianchi, Gerolamo | - |
dc.creator | Bolognese, Michael A. | - |
dc.creator | Christiansen, Claus Bohn | - |
dc.creator | Eastell, Richard | - |
dc.creator | Grauer, Andreas | - |
dc.creator | Hawkins, Federico | - |
dc.creator | Kendler, David L. | - |
dc.creator | Oliveri, María Beatriz | - |
dc.creator | McClung, Michael R. | - |
dc.creator | Reid, Ian R. | - |
dc.creator | Siris, Ethel S. | - |
dc.creator | Zanchetta, Jose | - |
dc.creator | Zerbini, Cristiano A.F. | - |
dc.creator | Libanati, Cesar | - |
dc.creator | Cummings, Steven R. | - |
dc.date | 2019-01-04T18:38:20Z | - |
dc.date | 2019-01-04T18:38:20Z | - |
dc.date | 2012-03 | - |
dc.date | 2019-01-02T19:40:11Z | - |
dc.date.accessioned | 2019-04-29T15:30:00Z | - |
dc.date.available | 2019-04-29T15:30:00Z | - |
dc.date.issued | 2019-01-04T18:38:20Z | - |
dc.date.issued | 2019-01-04T18:38:20Z | - |
dc.date.issued | 2012-03 | - |
dc.date.issued | 2019-01-02T19:40:11Z | - |
dc.identifier | Austin, Matthew; Yang, Yu Ching; Vittinghoff, Eric; Adami, Silvano; Boonen, Steven; et al.; Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures; American Society for Bone and Mineral Research; Journal of Bone and Mineral Research; 27; 3; 3-2012; 687-693 | - |
dc.identifier | 0884-0431 | - |
dc.identifier | http://hdl.handle.net/11336/67431 | - |
dc.identifier | CONICET Digital | - |
dc.identifier | CONICET | - |
dc.identifier.uri | http://rodna.bn.gov.ar:8080/jspui/handle/bnmm/295246 | - |
dc.description | Dual-energy X-ray absorptiometric bone mineral density (DXA BMD) is a strong predictor of fracture risk in untreated patients. However, previous patient-level studies suggest that BMD changes explain little of the fracture risk reduction observed with osteoporosis treatment. We investigated the relevance of DXA BMD changes as a predictor for fracture risk reduction using data from the FREEDOM trial, which randomly assigned placebo or denosumab 60 mg every 6 months to 7808 women aged 60 to 90 years with a spine or total hip BMD T-score < -2.5 and not < -4.0. We took a standard approach to estimate the percent of treatment effect explained using percent changes in BMD at a single visit (months 12, 24, or 36). We also applied a novel approach using estimated percent changes in BMD from baseline at the time of fracture occurrence (time-dependent models). Denosumab significantly increased total hip BMD by 3.2%, 4.4%, and 5.0% at 12, 24, and 36 months, respectively. Denosumab decreased the risk of new vertebral fractures by 68% (p < 0.0001) and nonvertebral fracture by 20% (p = 0.01) over 36 months. Regardless of the method used, the change in total hip BMD explained a considerable proportion of the effect of denosumab in reducing new or worsening vertebral fracture risk (35% [95% confidence interval (CI): 20%-61%] and 51% [95% CI: 39%-66%] accounted for by percent change at month 36 and change in time-dependent BMD, respectively) and explained a considerable amount of the reduction in nonvertebral fracture risk (87% [95% CI: 35% - >100%] and 72% [95% CI: 24% - >100%], respectively). Previous patient-level studies may have underestimated the strength of the relationship between BMD change and the effect of treatment on fracture risk or this relationship may be unique to denosumab. Copyright © 2012 American Society for Bone and Mineral Research. | - |
dc.description | Fil: Austin, Matthew. Amgen Incorporated; Estados Unidos | - |
dc.description | Fil: Yang, Yu Ching. Amgen Incorporated; Estados Unidos | - |
dc.description | Fil: Vittinghoff, Eric. University of California; Estados Unidos | - |
dc.description | Fil: Adami, Silvano. Universita di Verona; Italia | - |
dc.description | Fil: Boonen, Steven. Katholikie Universiteit Leuven; Bélgica | - |
dc.description | Fil: Bauer, Douglas C. University of California; Estados Unidos | - |
dc.description | Fil: Bianchi, Gerolamo. Azienda Sanitaria Genovese; Italia | - |
dc.description | Fil: Bolognese, Michael A.. Bethesda Health Research Center; Estados Unidos | - |
dc.description | Fil: Christiansen, Claus Bohn. Center For Clinical And Basic Research As; Estados Unidos | - |
dc.description | Fil: Eastell, Richard. University Of Sheffield; Reino Unido | - |
dc.description | Fil: Grauer, Andreas. Amgen Incorporated; Estados Unidos | - |
dc.description | Fil: Hawkins, Federico. Hospital Universitario 12 de Octubre; España | - |
dc.description | Fil: Kendler, David L.. University of British Columbia; Canadá | - |
dc.description | Fil: Oliveri, María Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina | - |
dc.description | Fil: McClung, Michael R.. Oregon Osteoporosis Center; Estados Unidos | - |
dc.description | Fil: Reid, Ian R.. The University of Auckland; Nueva Zelanda | - |
dc.description | Fil: Siris, Ethel S.. Columbia University; Estados Unidos | - |
dc.description | Fil: Zanchetta, Jose. Universidad del Salvador; Argentina | - |
dc.description | Fil: Zerbini, Cristiano A.F.. Centro Paulista de Investigação Clinica; Brasil | - |
dc.description | Fil: Libanati, Cesar. Amgen Incorporated; Estados Unidos | - |
dc.description | Fil: Cummings, Steven R.. University of California; Estados Unidos | - |
dc.format | application/pdf | - |
dc.format | application/pdf | - |
dc.language | eng | - |
dc.publisher | American Society for Bone and Mineral Research | - |
dc.relation | info:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1002/jbmr.1472 | - |
dc.relation | info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/full/10.1002/jbmr.1472 | - |
dc.rights | info:eu-repo/semantics/restrictedAccess | - |
dc.rights | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | - |
dc.source | reponame:CONICET Digital (CONICET) | - |
dc.source | instname:Consejo Nacional de Investigaciones Científicas y Técnicas | - |
dc.source | instacron:CONICET | - |
dc.source.uri | http://hdl.handle.net/11336/45474 | - |
dc.subject | BONE MINERAL DENSITY | - |
dc.subject | DENOSUMAB | - |
dc.subject | FRACTURE | - |
dc.subject | PERCENT OF TREATMENT EFFECT EXPLAINED | - |
dc.subject | SURROGATE | - |
dc.subject | Medicina Critica y de Emergencia | - |
dc.subject | Medicina Clínica | - |
dc.subject | CIENCIAS MÉDICAS Y DE LA SALUD | - |
dc.title | Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.type | info:ar-repo/semantics/articulo | - |
Aparece en las colecciones: | CONICET |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.